Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

@article{Gnant2013EffectOE,
  title={Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.},
  author={Michael Gnant and Jos{\'e} Baselga and Hope S Rugo and Shinzaburo Noguchi and Howard A. Burris and Martine J. Piccart and Gabriel N Hortobagyi and Janice F. Eakle and Hirofumi Mukai and Hiroji Iwata and Matthias Geberth and Lowell L. Hart and Peyman Hadji and Mona El-Hashimy and Shantha Rao and Tetiana Taran and Tarek Sahmoud and David Edward Lebwohl and Mario Campone and Kathleen I. Pritchard},
  journal={Journal of the National Cancer Institute},
  year={2013},
  volume={105 9},
  pages={
          654-63
        }
}
BACKGROUND Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor-positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. Moreover, in preclinical studies, mammalian target of rapamycin inhibition was associated with decreased osteoclast survival and activity. Exploratory analyses in BOLERO-2 evaluated the effect of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
28 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Effects of exemestane administered for 2 years versus placebo on bone mineral density , bone biomarkers , and plasma lipids in patients with surgically resected early breast cancer

  • PE Lonning, J Geisler, LE Krag
  • Int J Cancer
  • 2010

Similar Papers

Loading similar papers…